TRELLIS BIOSCIENCE, INC. — Department of Health and Human Services SBIR Phase II: NIAID

Description

Abstract About of serious bacterial infections are biofilm mediated Not only do biofilms provide an anchor and physical protection from the immune system for bacterial cells but the physiology and genetic programming of bacteria also shifts between the planktonic free floating and sessile stationary states Most notably antibiotic sensitivity differs substantially between the two states with bacteria being orders of magnitude less sensitive to antibiotics in the sessile state Biofilms are known to include a variety of polymers and proteins One of these proteins has previously been shown to anchor the three dimensional scaffolding of the polymers Trellis has used its proprietary antibody discovery technology to clone a high affinity antibody from human B lymphocytes TRL which binds the homologs of this protein from both Gram positive and Gram negative bacteria In Phase I of this project we used two rodent models of bacterial infection to demonstrate that extraction of the protein from the biofilm by this antibody leads to the biofilm dissolving in vivo as it does in vitro Therapeutic benefit was seen for treatment of MRSA in both models a rat model of infective endocarditis and a mouse model of implant infection In Phase II we will conduct IND enabling studies for FDA approval by establishing a manufacturing method under GMP and conducting toxicity testing of the therapeutic antibody In parallel we will continue preclinical research to explore alternative indications and dosing regimens This antibody offers potential clinical benefit against a wide range of infections that are currently very difficult to treat Infective endocarditis in particular is a an indication for which current therapy often fails leading to expensive heart valve replacement surgery that has a significant relapse rate re establishment of the biofilm protected infection leading to death Because the biofilm can be imaged directly using trans esophageal echocardiogram technology efficacy defined by clinical endpoints can be correlated with the mechanism of action Since the heart valve is readily accessible to antibody delivered intravenously tissue penetration is not a significant variable for this indication The combination of high unmet medical need and favorable experimental features makes this indication particularly useful for our initial clinical trials Narrative Following a successful Phase I in vivo test of a native human monoclonal antibody with specificity for a key protein component of bacterial biofilms we propose to initiate formal development leading towards an IND Manufacturing development toxicity testing and preclinical dose optimization will be carried out This antibody offers potential clinical benefit against a wide range of infections that are currently very difficult to treat